HC Wainwright & Co. Reiterates Buy on Acelyrin, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on Acelyrin (NASDAQ:SLRN) and maintained a $28 price target.
April 01, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acelyrin maintains a Buy rating and a $28 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a maintained price target of $28 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Acelyrin. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100